-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongxing Medical announced that in order to optimize the balance and liability structure of its wholly-owned subsidiary, the company plans to increase Dongxing Huamei's capital by 909.18,700 yuan through debt-to-equity swaps, of which 90 million yuan is included in the registered capital and 918,700 yuan in the capital reserve; and 354.49 million yuan of which 35 million yuan is included in the registered capital and 414,900 yuan in the capital reserve. After the capital increase was completed, the registered capital of Dongxing Huamei increased from 50 million yuan to 140 million yuan, and the registered capital of Zihang Precision increased from 5 million yuan to 40 million yuan. The two companies are still wholly-owned subsidiaries of the company and will not cause changes in the scope of the consolidated statement. The capital increase has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for consideration, and it does not constitute a related transaction or major asset restructuring.

Zhitongcaijing·11/16/2026 08:25:08
Listen to the news
Dongxing Medical announced that in order to optimize the balance and liability structure of its wholly-owned subsidiary, the company plans to increase Dongxing Huamei's capital by 909.18,700 yuan through debt-to-equity swaps, of which 90 million yuan is included in the registered capital and 918,700 yuan in the capital reserve; and 354.49 million yuan of which 35 million yuan is included in the registered capital and 414,900 yuan in the capital reserve. After the capital increase was completed, the registered capital of Dongxing Huamei increased from 50 million yuan to 140 million yuan, and the registered capital of Zihang Precision increased from 5 million yuan to 40 million yuan. The two companies are still wholly-owned subsidiaries of the company, and will not cause changes in the scope of the consolidated statement. The capital increase has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for consideration, and it does not constitute a related transaction or major asset restructuring.